Electromedical Technologies, Inc.
Electromedical Technologies, Inc. (EMED) Stock Competitors & Peer Comparison
See (EMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EMED | $0.00 | +0.00% | 171K | -0.02 | -$0.01 | N/A |
| SMMNY | $21.02 | -0.47% | 94.8B | 19.31 | $1.09 | +1.75% |
| SEMHF | $41.55 | -2.17% | 46.4B | 19.06 | $2.18 | +2.09% |
| RYLPF | $26.46 | +0.00% | 25.2B | 24.73 | $1.07 | +3.61% |
| SNNUF | $16.05 | +0.00% | 13.6B | 22.29 | $0.72 | +2.44% |
| SONVY | $44.96 | +0.02% | 13.4B | 20.65 | $2.18 | +2.40% |
| SONVF | $225.00 | +4.80% | 13.4B | 20.66 | $10.89 | +2.41% |
| CHEOY | $61.13 | +3.61% | 8B | 33.57 | $1.82 | +2.15% |
| CHEOF | $115.03 | +0.00% | 7.5B | 27.99 | $4.11 | +2.55% |
| WILYY | $15.41 | +14.57% | 6.6B | 17.39 | $0.86 | N/A |
Stock Comparison
EMED vs SMMNY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SMMNY has a market cap of 94.8B. Regarding current trading prices, EMED is priced at $0.00, while SMMNY trades at $21.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SMMNY's P/E ratio is 19.31. In terms of profitability, EMED's ROE is +0.27%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, EMED is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check SMMNY's competition here
EMED vs SEMHF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SEMHF has a market cap of 46.4B. Regarding current trading prices, EMED is priced at $0.00, while SEMHF trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SEMHF's P/E ratio is 19.06. In terms of profitability, EMED's ROE is +0.27%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, EMED is more volatile compared to SEMHF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check SEMHF's competition here
EMED vs RYLPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, RYLPF has a market cap of 25.2B. Regarding current trading prices, EMED is priced at $0.00, while RYLPF trades at $26.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas RYLPF's P/E ratio is 24.73. In terms of profitability, EMED's ROE is +0.27%, compared to RYLPF's ROE of +0.08%. Regarding short-term risk, EMED is more volatile compared to RYLPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check RYLPF's competition here
EMED vs SNNUF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SNNUF has a market cap of 13.6B. Regarding current trading prices, EMED is priced at $0.00, while SNNUF trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SNNUF's P/E ratio is 22.29. In terms of profitability, EMED's ROE is +0.27%, compared to SNNUF's ROE of +0.12%. Regarding short-term risk, EMED is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check SNNUF's competition here
EMED vs SONVY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SONVY has a market cap of 13.4B. Regarding current trading prices, EMED is priced at $0.00, while SONVY trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SONVY's P/E ratio is 20.65. In terms of profitability, EMED's ROE is +0.27%, compared to SONVY's ROE of +0.20%. Regarding short-term risk, EMED is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check SONVY's competition here
EMED vs SONVF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SONVF has a market cap of 13.4B. Regarding current trading prices, EMED is priced at $0.00, while SONVF trades at $225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SONVF's P/E ratio is 20.66. In terms of profitability, EMED's ROE is +0.27%, compared to SONVF's ROE of +0.20%. Regarding short-term risk, EMED is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check SONVF's competition here
EMED vs CHEOY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CHEOY has a market cap of 8B. Regarding current trading prices, EMED is priced at $0.00, while CHEOY trades at $61.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CHEOY's P/E ratio is 33.57. In terms of profitability, EMED's ROE is +0.27%, compared to CHEOY's ROE of +0.18%. Regarding short-term risk, EMED is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CHEOY's competition here
EMED vs CHEOF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CHEOF has a market cap of 7.5B. Regarding current trading prices, EMED is priced at $0.00, while CHEOF trades at $115.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CHEOF's P/E ratio is 27.99. In terms of profitability, EMED's ROE is +0.27%, compared to CHEOF's ROE of +0.18%. Regarding short-term risk, EMED is more volatile compared to CHEOF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CHEOF's competition here
EMED vs WILYY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, WILYY has a market cap of 6.6B. Regarding current trading prices, EMED is priced at $0.00, while WILYY trades at $15.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas WILYY's P/E ratio is 17.39. In terms of profitability, EMED's ROE is +0.27%, compared to WILYY's ROE of +0.16%. Regarding short-term risk, EMED is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check WILYY's competition here
EMED vs WILLF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, WILLF has a market cap of 6B. Regarding current trading prices, EMED is priced at $0.00, while WILLF trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas WILLF's P/E ratio is 16.36. In terms of profitability, EMED's ROE is +0.27%, compared to WILLF's ROE of +0.16%. Regarding short-term risk, EMED is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check WILLF's competition here
EMED vs GNGBF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, GNGBF has a market cap of 5.9B. Regarding current trading prices, EMED is priced at $0.00, while GNGBF trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas GNGBF's P/E ratio is 25.25. In terms of profitability, EMED's ROE is +0.27%, compared to GNGBF's ROE of +0.08%. Regarding short-term risk, EMED is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check GNGBF's competition here
EMED vs GNGBY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, GNGBY has a market cap of 5.7B. Regarding current trading prices, EMED is priced at $0.00, while GNGBY trades at $20.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas GNGBY's P/E ratio is 22.78. In terms of profitability, EMED's ROE is +0.27%, compared to GNGBY's ROE of +0.08%. Regarding short-term risk, EMED is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check GNGBY's competition here
EMED vs AMBFF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, AMBFF has a market cap of 3.7B. Regarding current trading prices, EMED is priced at $0.00, while AMBFF trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas AMBFF's P/E ratio is 42.66. In terms of profitability, EMED's ROE is +0.27%, compared to AMBFF's ROE of +0.09%. Regarding short-term risk, EMED is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check AMBFF's competition here
EMED vs NHNKY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, NHNKY has a market cap of 3.1B. Regarding current trading prices, EMED is priced at $0.00, while NHNKY trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas NHNKY's P/E ratio is 13.77. In terms of profitability, EMED's ROE is +0.27%, compared to NHNKY's ROE of +0.07%. Regarding short-term risk, EMED is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check NHNKY's competition here
EMED vs MCRPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, MCRPF has a market cap of 2.9B. Regarding current trading prices, EMED is priced at $0.00, while MCRPF trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas MCRPF's P/E ratio is -17.44. In terms of profitability, EMED's ROE is +0.27%, compared to MCRPF's ROE of -0.27%. Regarding short-term risk, EMED is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check MCRPF's competition here
EMED vs AMBBY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, AMBBY has a market cap of 2.8B. Regarding current trading prices, EMED is priced at $0.00, while AMBBY trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas AMBBY's P/E ratio is 34.10. In terms of profitability, EMED's ROE is +0.27%, compared to AMBBY's ROE of +0.09%. Regarding short-term risk, EMED is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check AMBBY's competition here
EMED vs NHNKF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, NHNKF has a market cap of 2.4B. Regarding current trading prices, EMED is priced at $0.00, while NHNKF trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, EMED's ROE is +0.27%, compared to NHNKF's ROE of +0.07%. Regarding short-term risk, EMED is less volatile compared to NHNKF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check NHNKF's competition here
EMED vs GNNDY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, GNNDY has a market cap of 2.3B. Regarding current trading prices, EMED is priced at $0.00, while GNNDY trades at $46.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas GNNDY's P/E ratio is 22.66. In terms of profitability, EMED's ROE is +0.27%, compared to GNNDY's ROE of +0.06%. Regarding short-term risk, EMED is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check GNNDY's competition here
EMED vs DRWKF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, DRWKF has a market cap of 2.1B. Regarding current trading prices, EMED is priced at $0.00, while DRWKF trades at $109.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas DRWKF's P/E ratio is 12.84. In terms of profitability, EMED's ROE is +0.27%, compared to DRWKF's ROE of +0.09%. Regarding short-term risk, EMED is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check DRWKF's competition here
EMED vs GGNDF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, GGNDF has a market cap of 2B. Regarding current trading prices, EMED is priced at $0.00, while GGNDF trades at $13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas GGNDF's P/E ratio is 19.93. In terms of profitability, EMED's ROE is +0.27%, compared to GGNDF's ROE of +0.06%. Regarding short-term risk, EMED is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check GGNDF's competition here
EMED vs FDMDF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, FDMDF has a market cap of 1.8B. Regarding current trading prices, EMED is priced at $0.00, while FDMDF trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas FDMDF's P/E ratio is -11.29. In terms of profitability, EMED's ROE is +0.27%, compared to FDMDF's ROE of -9.21%. Regarding short-term risk, EMED is more volatile compared to FDMDF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check FDMDF's competition here
EMED vs OSSFF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, OSSFF has a market cap of 1.8B. Regarding current trading prices, EMED is priced at $0.00, while OSSFF trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas OSSFF's P/E ratio is 20.75. In terms of profitability, EMED's ROE is +0.27%, compared to OSSFF's ROE of +0.10%. Regarding short-term risk, EMED is more volatile compared to OSSFF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check OSSFF's competition here
EMED vs DWRKF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, EMED is priced at $0.00, while DWRKF trades at $543.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, EMED's ROE is +0.27%, compared to DWRKF's ROE of N/A. Regarding short-term risk, EMED is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check DWRKF's competition here
EMED vs STSEY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, STSEY has a market cap of 1.7B. Regarding current trading prices, EMED is priced at $0.00, while STSEY trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas STSEY's P/E ratio is 19.00. In terms of profitability, EMED's ROE is +0.27%, compared to STSEY's ROE of +0.07%. Regarding short-term risk, EMED is more volatile compared to STSEY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check STSEY's competition here
EMED vs MEDGF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, EMED is priced at $0.00, while MEDGF trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, EMED's ROE is +0.27%, compared to MEDGF's ROE of +0.22%. Regarding short-term risk, EMED is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check MEDGF's competition here
EMED vs OSSUY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, OSSUY has a market cap of 1.6B. Regarding current trading prices, EMED is priced at $0.00, while OSSUY trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas OSSUY's P/E ratio is 19.08. In terms of profitability, EMED's ROE is +0.27%, compared to OSSUY's ROE of +0.10%. Regarding short-term risk, EMED is more volatile compared to OSSUY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check OSSUY's competition here
EMED vs VTRLY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, VTRLY has a market cap of 1.5B. Regarding current trading prices, EMED is priced at $0.00, while VTRLY trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas VTRLY's P/E ratio is -2.81. In terms of profitability, EMED's ROE is +0.27%, compared to VTRLY's ROE of -0.42%. Regarding short-term risk, EMED is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check VTRLY's competition here
EMED vs DGWPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, DGWPF has a market cap of 1.5B. Regarding current trading prices, EMED is priced at $0.00, while DGWPF trades at $76.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas DGWPF's P/E ratio is 8.96. In terms of profitability, EMED's ROE is +0.27%, compared to DGWPF's ROE of +0.09%. Regarding short-term risk, EMED is more volatile compared to DGWPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check DGWPF's competition here
EMED vs MDRSF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, MDRSF has a market cap of 1.4B. Regarding current trading prices, EMED is priced at $0.00, while MDRSF trades at $115.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas MDRSF's P/E ratio is 136.90. In terms of profitability, EMED's ROE is +0.27%, compared to MDRSF's ROE of +0.03%. Regarding short-term risk, EMED is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check MDRSF's competition here
EMED vs ELEAF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ELEAF has a market cap of 1.3B. Regarding current trading prices, EMED is priced at $0.00, while ELEAF trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ELEAF's P/E ratio is 23.06. In terms of profitability, EMED's ROE is +0.27%, compared to ELEAF's ROE of +0.16%. Regarding short-term risk, EMED is more volatile compared to ELEAF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ELEAF's competition here
EMED vs LFTSF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, LFTSF has a market cap of 1B. Regarding current trading prices, EMED is priced at $0.00, while LFTSF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, EMED's ROE is +0.27%, compared to LFTSF's ROE of +0.02%. Regarding short-term risk, EMED is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check LFTSF's competition here
EMED vs XVIPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, XVIPF has a market cap of 718.5M. Regarding current trading prices, EMED is priced at $0.00, while XVIPF trades at $22.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas XVIPF's P/E ratio is 285.14. In terms of profitability, EMED's ROE is +0.27%, compared to XVIPF's ROE of +0.01%. Regarding short-term risk, EMED is more volatile compared to XVIPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check XVIPF's competition here
EMED vs AVMR Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, EMED is priced at $0.00, while AVMR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas AVMR's P/E ratio is -18.34. In terms of profitability, EMED's ROE is +0.27%, compared to AVMR's ROE of -0.30%. Regarding short-term risk, EMED is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check AVMR's competition here
EMED vs DMTRF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, DMTRF has a market cap of 476M. Regarding current trading prices, EMED is priced at $0.00, while DMTRF trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas DMTRF's P/E ratio is -198.00. In terms of profitability, EMED's ROE is +0.27%, compared to DMTRF's ROE of +0.36%. Regarding short-term risk, EMED is less volatile compared to DMTRF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check DMTRF's competition here
EMED vs BRSYF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, BRSYF has a market cap of 475.2M. Regarding current trading prices, EMED is priced at $0.00, while BRSYF trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas BRSYF's P/E ratio is 74.19. In terms of profitability, EMED's ROE is +0.27%, compared to BRSYF's ROE of +0.12%. Regarding short-term risk, EMED is more volatile compared to BRSYF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check BRSYF's competition here
EMED vs IOBCF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, IOBCF has a market cap of 439.6M. Regarding current trading prices, EMED is priced at $0.00, while IOBCF trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas IOBCF's P/E ratio is 30.00. In terms of profitability, EMED's ROE is +0.27%, compared to IOBCF's ROE of +0.10%. Regarding short-term risk, EMED is more volatile compared to IOBCF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check IOBCF's competition here
EMED vs CALZF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CALZF has a market cap of 414.5M. Regarding current trading prices, EMED is priced at $0.00, while CALZF trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CALZF's P/E ratio is 60.00. In terms of profitability, EMED's ROE is +0.27%, compared to CALZF's ROE of +0.12%. Regarding short-term risk, EMED is more volatile compared to CALZF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CALZF's competition here
EMED vs CLVSF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CLVSF has a market cap of 384.8M. Regarding current trading prices, EMED is priced at $0.00, while CLVSF trades at $16.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CLVSF's P/E ratio is 23.73. In terms of profitability, EMED's ROE is +0.27%, compared to CLVSF's ROE of +0.18%. Regarding short-term risk, EMED is more volatile compared to CLVSF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CLVSF's competition here
EMED vs CSSPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CSSPF has a market cap of 384.5M. Regarding current trading prices, EMED is priced at $0.00, while CSSPF trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CSSPF's P/E ratio is 92.00. In terms of profitability, EMED's ROE is +0.27%, compared to CSSPF's ROE of +0.10%. Regarding short-term risk, EMED is more volatile compared to CSSPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CSSPF's competition here
EMED vs HYBT Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, EMED is priced at $0.00, while HYBT trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas HYBT's P/E ratio is N/A. In terms of profitability, EMED's ROE is +0.27%, compared to HYBT's ROE of +0.02%. Regarding short-term risk, EMED is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check HYBT's competition here
EMED vs CYBQY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CYBQY has a market cap of 291.8M. Regarding current trading prices, EMED is priced at $0.00, while CYBQY trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CYBQY's P/E ratio is -163.60. In terms of profitability, EMED's ROE is +0.27%, compared to CYBQY's ROE of -0.00%. Regarding short-term risk, EMED is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CYBQY's competition here
EMED vs HTLZF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, EMED is priced at $0.00, while HTLZF trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, EMED's ROE is +0.27%, compared to HTLZF's ROE of -0.01%. Regarding short-term risk, EMED is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check HTLZF's competition here
EMED vs CYBQF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CYBQF has a market cap of 229.5M. Regarding current trading prices, EMED is priced at $0.00, while CYBQF trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CYBQF's P/E ratio is -172.00. In terms of profitability, EMED's ROE is +0.27%, compared to CYBQF's ROE of -0.00%. Regarding short-term risk, EMED is more volatile compared to CYBQF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CYBQF's competition here
EMED vs IMPZY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, IMPZY has a market cap of 209.3M. Regarding current trading prices, EMED is priced at $0.00, while IMPZY trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, EMED's ROE is +0.27%, compared to IMPZY's ROE of +13.22%. Regarding short-term risk, EMED is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check IMPZY's competition here
EMED vs VMTHF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, VMTHF has a market cap of 184.7M. Regarding current trading prices, EMED is priced at $0.00, while VMTHF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas VMTHF's P/E ratio is -2.01. In terms of profitability, EMED's ROE is +0.27%, compared to VMTHF's ROE of -0.30%. Regarding short-term risk, EMED is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check VMTHF's competition here
EMED vs DTXMF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, DTXMF has a market cap of 180.6M. Regarding current trading prices, EMED is priced at $0.00, while DTXMF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas DTXMF's P/E ratio is -9.52. In terms of profitability, EMED's ROE is +0.27%, compared to DTXMF's ROE of -0.74%. Regarding short-term risk, EMED is less volatile compared to DTXMF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check DTXMF's competition here
EMED vs PXMBF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, PXMBF has a market cap of 149.9M. Regarding current trading prices, EMED is priced at $0.00, while PXMBF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, EMED's ROE is +0.27%, compared to PXMBF's ROE of -0.04%. Regarding short-term risk, EMED is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check PXMBF's competition here
EMED vs EKDHF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, EKDHF has a market cap of 146.6M. Regarding current trading prices, EMED is priced at $0.00, while EKDHF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas EKDHF's P/E ratio is 33.98. In terms of profitability, EMED's ROE is +0.27%, compared to EKDHF's ROE of +0.03%. Regarding short-term risk, EMED is more volatile compared to EKDHF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check EKDHF's competition here
EMED vs CLLKF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CLLKF has a market cap of 131.6M. Regarding current trading prices, EMED is priced at $0.00, while CLLKF trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CLLKF's P/E ratio is -0.81. In terms of profitability, EMED's ROE is +0.27%, compared to CLLKF's ROE of -0.50%. Regarding short-term risk, EMED is more volatile compared to CLLKF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CLLKF's competition here
EMED vs EAPIF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, EAPIF has a market cap of 120.9M. Regarding current trading prices, EMED is priced at $0.00, while EAPIF trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas EAPIF's P/E ratio is -0.84. In terms of profitability, EMED's ROE is +0.27%, compared to EAPIF's ROE of -0.24%. Regarding short-term risk, EMED is more volatile compared to EAPIF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check EAPIF's competition here
EMED vs AMEUF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, EMED is priced at $0.00, while AMEUF trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, EMED's ROE is +0.27%, compared to AMEUF's ROE of -1.90%. Regarding short-term risk, EMED is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check AMEUF's competition here
EMED vs SOMNF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SOMNF has a market cap of 111.7M. Regarding current trading prices, EMED is priced at $0.00, while SOMNF trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SOMNF's P/E ratio is -51.00. In terms of profitability, EMED's ROE is +0.27%, compared to SOMNF's ROE of -0.05%. Regarding short-term risk, EMED is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check SOMNF's competition here
EMED vs BCCOY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, BCCOY has a market cap of 103.6M. Regarding current trading prices, EMED is priced at $0.00, while BCCOY trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas BCCOY's P/E ratio is -0.64. In terms of profitability, EMED's ROE is +0.27%, compared to BCCOY's ROE of -0.50%. Regarding short-term risk, EMED is less volatile compared to BCCOY. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check BCCOY's competition here
EMED vs AVHHL Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, AVHHL has a market cap of 99.4M. Regarding current trading prices, EMED is priced at $0.00, while AVHHL trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas AVHHL's P/E ratio is -2.22. In terms of profitability, EMED's ROE is +0.27%, compared to AVHHL's ROE of +4.77%. Regarding short-term risk, EMED is more volatile compared to AVHHL. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check AVHHL's competition here
EMED vs JMDMF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, JMDMF has a market cap of 94.1M. Regarding current trading prices, EMED is priced at $0.00, while JMDMF trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas JMDMF's P/E ratio is -13.68. In terms of profitability, EMED's ROE is +0.27%, compared to JMDMF's ROE of N/A. Regarding short-term risk, EMED is less volatile compared to JMDMF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check JMDMF's competition here
EMED vs RSHUF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, EMED is priced at $0.00, while RSHUF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, EMED's ROE is +0.27%, compared to RSHUF's ROE of -4.12%. Regarding short-term risk, EMED is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check RSHUF's competition here
EMED vs CKMTF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, EMED is priced at $0.00, while CKMTF trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, EMED's ROE is +0.27%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, EMED is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check CKMTF's competition here
EMED vs SNZZF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, SNZZF has a market cap of 75M. Regarding current trading prices, EMED is priced at $0.00, while SNZZF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas SNZZF's P/E ratio is -4.77. In terms of profitability, EMED's ROE is +0.27%, compared to SNZZF's ROE of -0.41%. Regarding short-term risk, EMED is less volatile compared to SNZZF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check SNZZF's competition here
EMED vs BLOZF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, BLOZF has a market cap of 63.8M. Regarding current trading prices, EMED is priced at $0.00, while BLOZF trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas BLOZF's P/E ratio is -13.16. In terms of profitability, EMED's ROE is +0.27%, compared to BLOZF's ROE of -3.03%. Regarding short-term risk, EMED is more volatile compared to BLOZF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check BLOZF's competition here
EMED vs TLTFF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, TLTFF has a market cap of 52.1M. Regarding current trading prices, EMED is priced at $0.00, while TLTFF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas TLTFF's P/E ratio is -20.25. In terms of profitability, EMED's ROE is +0.27%, compared to TLTFF's ROE of -3.15%. Regarding short-term risk, EMED is more volatile compared to TLTFF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check TLTFF's competition here
EMED vs BRNHF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, BRNHF has a market cap of 42.1M. Regarding current trading prices, EMED is priced at $0.00, while BRNHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas BRNHF's P/E ratio is -1.33. In terms of profitability, EMED's ROE is +0.27%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, EMED is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check BRNHF's competition here
EMED vs RDGL Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, RDGL has a market cap of 40.3M. Regarding current trading prices, EMED is priced at $0.00, while RDGL trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas RDGL's P/E ratio is -8.86. In terms of profitability, EMED's ROE is +0.27%, compared to RDGL's ROE of -1.26%. Regarding short-term risk, EMED is more volatile compared to RDGL. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check RDGL's competition here
EMED vs NVYTF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, NVYTF has a market cap of 34.8M. Regarding current trading prices, EMED is priced at $0.00, while NVYTF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas NVYTF's P/E ratio is -0.86. In terms of profitability, EMED's ROE is +0.27%, compared to NVYTF's ROE of -0.73%. Regarding short-term risk, EMED is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check NVYTF's competition here
EMED vs PYNKF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, PYNKF has a market cap of 29.7M. Regarding current trading prices, EMED is priced at $0.00, while PYNKF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas PYNKF's P/E ratio is 4.72. In terms of profitability, EMED's ROE is +0.27%, compared to PYNKF's ROE of -2.30%. Regarding short-term risk, EMED is more volatile compared to PYNKF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check PYNKF's competition here
EMED vs IPDQF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, IPDQF has a market cap of 27.1M. Regarding current trading prices, EMED is priced at $0.00, while IPDQF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas IPDQF's P/E ratio is -1.33. In terms of profitability, EMED's ROE is +0.27%, compared to IPDQF's ROE of -1.65%. Regarding short-term risk, EMED is more volatile compared to IPDQF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check IPDQF's competition here
EMED vs MKEAF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, EMED is priced at $0.00, while MKEAF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, EMED's ROE is +0.27%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, EMED is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check MKEAF's competition here
EMED vs POSC Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, POSC has a market cap of 25.4M. Regarding current trading prices, EMED is priced at $0.00, while POSC trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas POSC's P/E ratio is 0.38. In terms of profitability, EMED's ROE is +0.27%, compared to POSC's ROE of -3.78%. Regarding short-term risk, EMED is more volatile compared to POSC. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check POSC's competition here
EMED vs KBBTF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, EMED is priced at $0.00, while KBBTF trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, EMED's ROE is +0.27%, compared to KBBTF's ROE of N/A. Regarding short-term risk, EMED is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check KBBTF's competition here
EMED vs GTHP Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, GTHP has a market cap of 20.1M. Regarding current trading prices, EMED is priced at $0.00, while GTHP trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas GTHP's P/E ratio is -4.80. In terms of profitability, EMED's ROE is +0.27%, compared to GTHP's ROE of +1.39%. Regarding short-term risk, EMED is more volatile compared to GTHP. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check GTHP's competition here
EMED vs EMITF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, EMITF has a market cap of 20.1M. Regarding current trading prices, EMED is priced at $0.00, while EMITF trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas EMITF's P/E ratio is -8.57. In terms of profitability, EMED's ROE is +0.27%, compared to EMITF's ROE of -0.14%. Regarding short-term risk, EMED is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check EMITF's competition here
EMED vs DIZTF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, EMED is priced at $0.00, while DIZTF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, EMED's ROE is +0.27%, compared to DIZTF's ROE of -0.52%. Regarding short-term risk, EMED is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check DIZTF's competition here
EMED vs ASAPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ASAPF has a market cap of 16.2M. Regarding current trading prices, EMED is priced at $0.00, while ASAPF trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ASAPF's P/E ratio is -20.70. In terms of profitability, EMED's ROE is +0.27%, compared to ASAPF's ROE of -0.32%. Regarding short-term risk, EMED is more volatile compared to ASAPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ASAPF's competition here
EMED vs MDXHF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, MDXHF has a market cap of 14.4M. Regarding current trading prices, EMED is priced at $0.00, while MDXHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas MDXHF's P/E ratio is -4.40. In terms of profitability, EMED's ROE is +0.27%, compared to MDXHF's ROE of +0.58%. Regarding short-term risk, EMED is more volatile compared to MDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check MDXHF's competition here
EMED vs VPTDF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, VPTDF has a market cap of 14M. Regarding current trading prices, EMED is priced at $0.00, while VPTDF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas VPTDF's P/E ratio is -4.08. In terms of profitability, EMED's ROE is +0.27%, compared to VPTDF's ROE of +1.07%. Regarding short-term risk, EMED is more volatile compared to VPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check VPTDF's competition here
EMED vs TMDIF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, EMED is priced at $0.00, while TMDIF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, EMED's ROE is +0.27%, compared to TMDIF's ROE of +8.70%. Regarding short-term risk, EMED is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check TMDIF's competition here
EMED vs ATBPF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, EMED is priced at $0.00, while ATBPF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, EMED's ROE is +0.27%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, EMED is more volatile compared to ATBPF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ATBPF's competition here
EMED vs LXXGF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, EMED is priced at $0.00, while LXXGF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, EMED's ROE is +0.27%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, EMED is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check LXXGF's competition here
EMED vs RMSL Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, RMSL has a market cap of 10.9M. Regarding current trading prices, EMED is priced at $0.00, while RMSL trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas RMSL's P/E ratio is 0.68. In terms of profitability, EMED's ROE is +0.27%, compared to RMSL's ROE of -12.31%. Regarding short-term risk, EMED is more volatile compared to RMSL. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check RMSL's competition here
EMED vs PLLWF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, PLLWF has a market cap of 8M. Regarding current trading prices, EMED is priced at $0.00, while PLLWF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas PLLWF's P/E ratio is -0.66. In terms of profitability, EMED's ROE is +0.27%, compared to PLLWF's ROE of -0.99%. Regarding short-term risk, EMED is less volatile compared to PLLWF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check PLLWF's competition here
EMED vs USAQ Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, USAQ has a market cap of 7.8M. Regarding current trading prices, EMED is priced at $0.00, while USAQ trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas USAQ's P/E ratio is -17.24. In terms of profitability, EMED's ROE is +0.27%, compared to USAQ's ROE of -8.25%. Regarding short-term risk, EMED is more volatile compared to USAQ. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check USAQ's competition here
EMED vs ALRTF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ALRTF has a market cap of 7.4M. Regarding current trading prices, EMED is priced at $0.00, while ALRTF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ALRTF's P/E ratio is -0.29. In terms of profitability, EMED's ROE is +0.27%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, EMED is more volatile compared to ALRTF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ALRTF's competition here
EMED vs PMEDF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, PMEDF has a market cap of 7.1M. Regarding current trading prices, EMED is priced at $0.00, while PMEDF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas PMEDF's P/E ratio is -3.45. In terms of profitability, EMED's ROE is +0.27%, compared to PMEDF's ROE of +1.24%. Regarding short-term risk, EMED is more volatile compared to PMEDF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check PMEDF's competition here
EMED vs ADMT Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ADMT has a market cap of 6.1M. Regarding current trading prices, EMED is priced at $0.00, while ADMT trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ADMT's P/E ratio is -9.00. In terms of profitability, EMED's ROE is +0.27%, compared to ADMT's ROE of -0.01%. Regarding short-term risk, EMED is more volatile compared to ADMT. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ADMT's competition here
EMED vs ODYY Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ODYY has a market cap of 5.7M. Regarding current trading prices, EMED is priced at $0.00, while ODYY trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ODYY's P/E ratio is -1.14. In terms of profitability, EMED's ROE is +0.27%, compared to ODYY's ROE of +0.58%. Regarding short-term risk, EMED is more volatile compared to ODYY. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ODYY's competition here
EMED vs QLIS Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, EMED is priced at $0.00, while QLIS trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas QLIS's P/E ratio is 2.22. In terms of profitability, EMED's ROE is +0.27%, compared to QLIS's ROE of -0.60%. Regarding short-term risk, EMED is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check QLIS's competition here
EMED vs RHNMF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, EMED is priced at $0.00, while RHNMF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, EMED's ROE is +0.27%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, EMED is more volatile compared to RHNMF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check RHNMF's competition here
EMED vs BIEL Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, BIEL has a market cap of 5.4M. Regarding current trading prices, EMED is priced at $0.00, while BIEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas BIEL's P/E ratio is N/A. In terms of profitability, EMED's ROE is +0.27%, compared to BIEL's ROE of +0.05%. Regarding short-term risk, EMED is less volatile compared to BIEL. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check BIEL's competition here
EMED vs NGMDF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, NGMDF has a market cap of 4.1M. Regarding current trading prices, EMED is priced at $0.00, while NGMDF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas NGMDF's P/E ratio is -1.81. In terms of profitability, EMED's ROE is +0.27%, compared to NGMDF's ROE of +0.34%. Regarding short-term risk, EMED is less volatile compared to NGMDF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check NGMDF's competition here
EMED vs VANIW Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, EMED is priced at $0.00, while VANIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas VANIW's P/E ratio is N/A. In terms of profitability, EMED's ROE is +0.27%, compared to VANIW's ROE of -3.17%. Regarding short-term risk, EMED is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check VANIW's competition here
EMED vs CYDX Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, CYDX has a market cap of 3.3M. Regarding current trading prices, EMED is priced at $0.00, while CYDX trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas CYDX's P/E ratio is 0.82. In terms of profitability, EMED's ROE is +0.27%, compared to CYDX's ROE of +0.13%. Regarding short-term risk, EMED is less volatile compared to CYDX. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check CYDX's competition here
EMED vs VYCO Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, VYCO has a market cap of 3M. Regarding current trading prices, EMED is priced at $0.00, while VYCO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas VYCO's P/E ratio is -9.00. In terms of profitability, EMED's ROE is +0.27%, compared to VYCO's ROE of +0.00%. Regarding short-term risk, EMED is less volatile compared to VYCO. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check VYCO's competition here
EMED vs TBRIF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, TBRIF has a market cap of 2.8M. Regarding current trading prices, EMED is priced at $0.00, while TBRIF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas TBRIF's P/E ratio is -0.95. In terms of profitability, EMED's ROE is +0.27%, compared to TBRIF's ROE of +16.81%. Regarding short-term risk, EMED is more volatile compared to TBRIF. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check TBRIF's competition here
EMED vs LLBO Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, LLBO has a market cap of 2.2M. Regarding current trading prices, EMED is priced at $0.00, while LLBO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas LLBO's P/E ratio is N/A. In terms of profitability, EMED's ROE is +0.27%, compared to LLBO's ROE of +0.00%. Regarding short-term risk, EMED is more volatile compared to LLBO. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check LLBO's competition here
EMED vs KLYG Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, KLYG has a market cap of 1.9M. Regarding current trading prices, EMED is priced at $0.00, while KLYG trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas KLYG's P/E ratio is -15.00. In terms of profitability, EMED's ROE is +0.27%, compared to KLYG's ROE of -0.04%. Regarding short-term risk, EMED is less volatile compared to KLYG. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check KLYG's competition here
EMED vs VRSEF Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, VRSEF has a market cap of 1.4M. Regarding current trading prices, EMED is priced at $0.00, while VRSEF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas VRSEF's P/E ratio is 0.14. In terms of profitability, EMED's ROE is +0.27%, compared to VRSEF's ROE of +1.00%. Regarding short-term risk, EMED is less volatile compared to VRSEF. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check VRSEF's competition here
EMED vs FZMD Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, FZMD has a market cap of 1.3M. Regarding current trading prices, EMED is priced at $0.00, while FZMD trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas FZMD's P/E ratio is 1.72. In terms of profitability, EMED's ROE is +0.27%, compared to FZMD's ROE of +0.13%. Regarding short-term risk, EMED is less volatile compared to FZMD. This indicates potentially lower risk in terms of short-term price fluctuations for EMED.Check FZMD's competition here
EMED vs ESMC Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, ESMC has a market cap of 1M. Regarding current trading prices, EMED is priced at $0.00, while ESMC trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas ESMC's P/E ratio is -4.67. In terms of profitability, EMED's ROE is +0.27%, compared to ESMC's ROE of -125.28%. Regarding short-term risk, EMED is more volatile compared to ESMC. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check ESMC's competition here
EMED vs UAHC Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, UAHC has a market cap of 1M. Regarding current trading prices, EMED is priced at $0.00, while UAHC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas UAHC's P/E ratio is 0.73. In terms of profitability, EMED's ROE is +0.27%, compared to UAHC's ROE of +0.04%. Regarding short-term risk, EMED is more volatile compared to UAHC. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check UAHC's competition here
EMED vs NUMD Comparison April 2026
EMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMED stands at 171K. In comparison, NUMD has a market cap of 930.7K. Regarding current trading prices, EMED is priced at $0.00, while NUMD trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMED currently has a P/E ratio of -0.02, whereas NUMD's P/E ratio is 1.11. In terms of profitability, EMED's ROE is +0.27%, compared to NUMD's ROE of +0.23%. Regarding short-term risk, EMED is more volatile compared to NUMD. This indicates potentially higher risk in terms of short-term price fluctuations for EMED.Check NUMD's competition here